Codexis Inc
NASDAQ:CDXS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Codexis Inc
Intangible Assets
Codexis Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Codexis Inc
NASDAQ:CDXS
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Intangible Assets
$15.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Danaher Corp
NYSE:DHR
|
Intangible Assets
$17.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
|
Waters Corp
NYSE:WAT
|
Intangible Assets
$558.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
17%
|
CAGR 10-Years
10%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Intangible Assets
$426m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Intangible Assets
$5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
30%
|
|
Codexis Inc
Glance View
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).
